Membrane-Bound IL-12 Biocircuits for Tunable Protein Expression

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current gene therapy technologies lack the ability to titrate the timing or levels of target protein induction, rendering many applications difficult or impossible to safely and effectively deploy.

Innovation Solution

The use of destabilizing domains (DDs) in biocircuit systems with stimulus response elements (SREs) to regulate protein expression and function, allowing for tunable and temporal control of gene expression and function, particularly through the incorporation of membrane-associated Interleukin 12 (IL12) and CD19 chimeric antigen receptors (CAR) in modified cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If destabilizing domains (DDs) are used to regulate protein expression, then temporal control and titration of protein levels are achieved, but device complexity increases

Engineering Contradiction:
Improvecontrol precisionVSAvoidsystem complexity
Core Design Contradiction:
Measurement precisionVSDevice complexity

Solution Approach 1:

The system is divided into separate functional modules: destabilizing domains (DDs) that confer protein instability, stimulus response elements (SREs) that sense cellular conditions, and effector modules that execute the regulatory function. This segmentation allows independent optimization of each component and enables modular assembly of complex regulatory circuits with precise temporal and quantitative control.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

Destabilizing domains act as intermediary elements that translate stimulus signals into controlled protein degradation or stabilization. The DDs serve as a buffer layer between the stimulus sensing mechanism and the effector protein, enabling fine-tuned temporal control of protein expression levels without requiring direct transcriptional regulation.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If membrane-associated IL12 is used as payload, then therapeutic efficacy is improved, but manufacturing complexity increases

Engineering Contradiction:
Improvetherapeutic efficacyVSAvoidmanufacturing complexity
Core Design Contradiction:
ReliabilityVSEase of manufacture

Solution Approach 1:

The effector module design integrates multiple functions into a single construct: the membrane-associated IL12 payload provides both localized cytokine delivery and cell surface anchoring, while the attached SRE-DD combination provides autonomous regulatory control. This multi-functionality reduces the need for separate regulatory elements and simplifies the manufacturing process despite the enhanced therapeutic capability.

Inventive Principle:
Principle #6Universality (Multi-functionality)

Data Source

PatentEP3894011B1Membrane bound il12 compositions and methods for tunable regulation
Publication Date: 2025.09.17 OBSIDIAN THERAPEUTICS INC

AI summary

The present disclosure provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities.